Notes on verification

Figure of ~800 euros is corroborated by the ISS source and closely matches AGCM's ~900 euro figure and legal documents citing 902 euro; minor terminology inconsistency between 'treatment cycle' and 'single injection' across sources, and price varied over time (2007-2014). [tier=bronze indep_score=0.525 clusters=3 claim_tier=notable | framework convergence=partial on AGCM antitrust investigation and decision (provvedimento n. 24823 del 27.2.2014) on Roche/Novartis pricing data for Avastin and Lucentis (upstreams: Autorità Garante della Concorrenza e del Mercato (AGCM) 2014 antitrust decision) — publishers independent, evidence may not be | kind=attributed eligibility=medium]